Kiora Net Income From Continuing Ops from 2010 to 2024

KPRX Stock  USD 3.31  0.11  3.22%   
Kiora Pharmaceuticals Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -13.4 M in 2024. During the period from 2010 to 2024, Kiora Pharmaceuticals Net Loss regression line of annual values had significance of  0.67 and arithmetic mean of (12,523,106). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-12.7 M
Current Value
-13.4 M
Quarterly Volatility
2.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Kiora Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiora Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.2 K, Selling General Administrative of 4.8 M or Other Operating Expenses of 10.3 M, as well as many indicators such as Price To Sales Ratio of 16 K, Dividend Yield of 0.0 or PTB Ratio of 0.43. Kiora financial statements analysis is a perfect complement when working with Kiora Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Kiora Pharmaceuticals Correlation against competitors.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Latest Kiora Pharmaceuticals' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Kiora Pharmaceuticals over the last few years. It is Kiora Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Kiora Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(12,523,106)
Coefficient Of Variation(18.21)
Mean Deviation1,542,568
Median(13,217,917)
Standard Deviation2,279,932
Sample Variance5.2T
Range9.3M
R-Value0.12
Mean Square Error5.5T
R-Squared0.01
Significance0.67
Slope61,409
Total Sum of Squares72.8T

Kiora Net Income From Continuing Ops History

2024-13.4 M
2023-12.7 M
2022-13.6 M
2021-16.4 M
2020-8.1 M
2019-7.1 M
2018-10.8 M

About Kiora Pharmaceuticals Financial Statements

Kiora Pharmaceuticals investors use historical fundamental indicators, such as Kiora Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kiora Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-12.7 M-13.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.